Ocular Hypertension Pipeline Outlook Report 2024 | Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, and others

DelveInsight's, "Ocular Hypertension Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ocular Hypertension pipeline landscape. It covers the Ocular Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ocular Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ocular Hypertension Pipeline Report
• DelveInsight's Ocular Hypertension pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ocular Hypertension treatment.
• The leading Ocular Hypertension Companies include Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others.
• Promising Ocular Hypertension Pipeline Therapies include NCX-470, QLS-101, TO-O-1001, and others.
• March 2024: Omikron Italia S.R.L announced a study of Phase 3 clinical trials for Citicoline eye drops 2%. To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%
• March 2024: Qlaris Bio Inc. announced a study of Phase 2 clinical trials for Experimental: QLS-111 ophthalmic solution, (0.015%). Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
• December 2023: AbbVie announced a study of Phase 1 & 2 clinical trials for AGN-193408 SR and Lumigan. This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension.
• November 2023: Nicox Ophthalmics Inc. announced a study of Phase 3 clinical trials for NCX 470 0.1% and Latanoprost 0.005%. The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

Request a sample and discover the recent advances in Ocular Hypertension Treatment Drugs @ Ocular Hypertension Pipeline Report- https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Ocular Hypertension pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ocular Hypertension drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ocular Hypertension clinical trial landscape.

Ocular Hypertension Overview
Ocular hypertension occurs when the pressure inside the eye exceeds the range considered normal and goes higher than 21 mm Hg. The increase in intraocular pressure (progressive with age, although may also be due to other disorders or causes) is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease.

Find out more about Ocular Hypertension Treatment Landscape @ Drugs for Ocular Hypertension Treatment- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ocular Hypertension Emerging Drugs Profile
• NCX-470: Nicox
• QLS-101: Qlaris Bio
• TO-O-1001: TheratOcular Biotek Co., Ltd.

Ocular Hypertension Pipeline Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Ocular Hypertension. The Ocular Hypertension companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

DelveInsight's Ocular Hypertension pipeline report covers around 75+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Ocular Hypertension Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Ocular Hypertension Pipeline Therapies @ Ocular Hypertension Clinical Trials Assessment- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Ocular Hypertension Pipeline Report
• Coverage- Global
• Ocular Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ocular Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ocular Hypertension Companies- Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others.
• Ocular Hypertension Pipeline Therapies- NCX-470, QLS-101, TO-O-1001, and others.

Dive deep into rich insights for new drugs for Ocular Hypertension treatment, Visit @ Ocular Hypertension Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Ocular Hypertension: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ocular Hypertension- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. NCX-470: Nicox
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. QLS-101: Qlaris Bio
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. TO-O-1001: TheratOcular Biotek Co., Ltd.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ocular Hypertension Key Companies
21. Ocular Hypertension Key Products
22. Ocular Hypertension- Unmet Needs
23. Ocular Hypertension- Market Drivers and Barriers
24. Ocular Hypertension- Future Perspectives and Conclusion
25. Ocular Hypertension Analyst Views
26. Ocular Hypertension Key Companies
27. Appendix

For further information on the Ocular Hypertension Pipeline Therapeutics, reach out @ Ocular Hypertension Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://msnho.com/blog/understanding-sepsis-market-size-insights-delveinsight
https://instakos.mn.co/posts/53850138
https://godsoftheuniverse.mn.co/posts/53850353
https://www.montessorijobsuk.co.uk/author/germanydennydones/
https://www.magicscalemodeling.com/profile/ybhardwaj/profile
https://signalsnetwork.mn.co/posts/53853033
https://mynetsohbet.mn.co/posts/53853061
https://andrew-brown.mn.co/posts/53853088
https://pinkish.mn.co/posts/53865682
https://regionalhilfesozial.mn.co/posts/53865700
https://kyte-en-espanol.mn.co/posts/53865716
https://australian-school-holidays.mn.co/posts/53865999
https://dating-making-friends.mn.co/posts/53866131
https://lennor.mn.co/posts/53866232
https://linkmate.mn.co/posts/exploring-the-bone-growth-stimulator-market-insights-by-delveinsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

This release was published on openPR.